Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloretazine plus cytarabine versus placebo plus cytarabine in first-relapse acute myeloid leukemia
2004-004661-15Phase 3Terminated
- Sponsor
- Vion Pharmaceuticals
- Start
- Feb 2005
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Cloretazine + cytarabine with Placebo + cytarabine (2 arms). Primary endpoints: Overall response rate and CR/CRp rate. Started Feb 2005; status: terminated.
02
Drugs
laromustinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2004-004661-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004661-15.